Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IDE705
- Development stage
- Discontinued
- Lead developer
- IDEAYA Biosciences
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
IDE705 is a novel small molecule inhibitor targeting the helicase activity of DNA polymerase theta (Pol θ), also known as POLQ. It is being developed as a potential first-in-class therapy for solid tumors with homologous recombination deficiency (HRD). The drug is primarily investigated in combination with niraparib (a PARP inhibitor) to exploit synthetic lethality in HRD-positive cancers. IDE705 is under joint development by IDEAYA Biosciences and GSK and has entered Phase 1/2 clinical trials for advanced solid tumors[3][6][7]. Its mechanism involves inhibiting Pol θ-mediated DNA repair pathways that are critical for the survival of HR-deficient tumor cells.
- Brand names
- GSK101GSK-101GSK 101
- Other names
- DNA polymerase theta helicase inhibitor
02
Targets
POLQ (DNA polymerase theta)
Beyond the preview
Go deeper on IDE705.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IDE705.